VYGR
Voyager Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 3
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VYGR
Voyager Therapeutics, Inc.
A gene therapy and neuroscience company developing next-generation adeno-associated virus (AAV) capsids
Biological Technology
--
11/11/2015
NASDAQ Stock Exchange
172
12-31
Common stock
75 Hayden Avenue, Lexington, Massachusetts 02421
--
Voyager Therapeutics, Inc., was incorporated in June 2013 under the laws of the State of Delaware. The company is a biotechnology company dedicated to breaking through gene therapy and neurological barriers. The company's gene therapy platform enables them to design, optimize, manufacture and deliver AAV-based gene therapies that they believe have the potential to safely deliver long-lasting efficacy.
Company Financials
EPS
VYGR has released its 2025 Q3 earnings. EPS was reported at -0.47, versus the expected -0.52, beating expectations. The chart below visualizes how VYGR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VYGR has released its 2025 Q3 earnings report, with revenue of 13.37M, reflecting a YoY change of -45.73%, and net profit of -27.89M, showing a YoY change of -208.40%. The Sankey diagram below clearly presents VYGR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
